1450 Results
Sort By:
Published on February 20, 2018
Karius said today its next-generation sequencing (NGS) plasma test for pathogen detection will be used by Nohla Therapeutics will use in its Phase II trial evaluating the company’s lead product, NLA101, in acute myeloid leukemia (AML) patients with chemotherapy-induced neutropenia. The value of the clinical collaboration was not disclosed. Karius…
Published on February 12, 2018
A team of scientists in the U.S. and China has created programmable DNA origami nanorobots that can seek out and shrink tumors by blocking their blood supply. Tests in mice carrying breast, melanoma, ovarian, and lung tumors showed how the DNA nanorobots homed in on cancer-feeding blood vessels and induced…
Published on February 8, 2018
Cancer metastasis causes 90% of all cancer-related deaths. Scientists agree that the metastases occur when cancer cells are shed from the primary tumor, carried by the peripheral blood, and deposited at a distal site to create a new colony. An ability to etect circulating tumor cells (CTCs) or cell-free cancer…
Published on January 31, 2018
The FDA’s embrace of precision oncology, along with increases in the number and rate of survival, were highlighted today by the American Society of Clinical Oncology (ASCO) as examples of clinical progress in the fight against cancer. In “Clinical Care Advances 2018,” ASCO cited as its “Advance of the Year”…
Published on January 23, 2018
From immunotherapy to developments in gene editing, experts in the field weigh in on this year’s most important advances. Clinical OMICs spoke with Sheryl Elkin from N-of-One, Jonas Korlach from Pacific Biosciences, Eric Schadt from Sema4, Kevin Davies from The CRISPR Journal, Joydeep Goswami from Thermo Fisher Scientific, and Federico…
Published on January 17, 2018
Immuno-oncology diagnostics developer HalioDx said today it has closed on an €18.5 million ($22.6 million) Series B financing, with the proceeds to be used toward accelerating the development of its Immunoscore platform for selected cancers, as well as supporting commercial activities in the U.S. Specifically, HalioDx said it intends to…
Published on December 13, 2017
Researchers at the Francis Crick Institute have released new findings to show that Ras genes are not only the driver mutation for roughly 25% of all human cancers, but they also supress the immune sysem's anticancer response, helping to cloak cancer cells by boosting the expression of the protein programmed…
Published on December 11, 2017
Caris Life Sciences said today it has identified a new mechanism of action for an aptamer with potential to treat non-Hodgkin lymphoma (NHL), using its proprietary ADAPT Biotargeting System. At the 59th American Society of Hematology (ASH) Annual Meeting & Exposition in Atlanta, Caris presented results from a study, Aptamer C10.36…
Published on December 7, 2017
Thermo Fisher Scientific has received a coverage proposal from the Centers for Medicare & Medicaid Services (CMS) for its Oncomine Dx Target Test, a multi-biomarker non-small cell lung cancer (NSCLC) diagnostic, as part of a national coverage determination (NCD). The NCD covers next-generation sequencing (NGS) in vitro diagnostic (IVD) tests…
Published on December 1, 2017
FoundationOne CDx, a next-generation sequencing (NGS)-based in vitro diagnostic (IVD) from Foundation Medicine has gained FDA approval and a concurrent coverage proposal from the Centers for Medicare & Medicaid Services (CMS). Foundation One CDx detects substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes and…
Published on November 28, 2017
Biocept said today it will partner with University of California San Diego (UCSD) Medical Center on a clinical validation study of the company’s PD-L1 assay for patients diagnosed with non-small cell lung cancer (NSCLC). Under the collaboration, whose value was not disclosed, Sandip Patel, M.D., an assistant professor of UCSD…
Published on November 21, 2017
The Leukemia & Lymphoma Society (LLS) has committed an additional $46 million toward 87 new blood cancer research projects at institutions worldwide. The new funding will increase to 254 the number of grants in LLS's total active research portfolio—which according to the society represents more investment in blood cancer research…
Published on November 15, 2017
Sangamo Therapeutics said today that the first patient in the Phase I/II CHAMPIONS clinical trial has been treated with its in vivo genome editing candidate therapy SB-913 for mucopolysaccharidosis type II (MPS II), also called Hunter syndrome. “We are at the start of a new frontier of genomic medicine,” declared…
Published on November 8, 2017
Caris Life Sciences is accusing Foundation Medicine in a federal lawsuit of infringing on five Caris patents in the development of its cancer assays FoundationOne®, FoundationACT® and FoundationOne® Heme. “As a result of Defendant’s infringement and the threat of its continued infringement, Caris faces a substantial risk of irreparable harm,”…
Published on November 3, 2017
Epic Sciences said it will add simultaneous microsatellite instability (MSI) and chromosomal instability (CIN) measurements—also called genomic scarring analysis—to its single cell next generation sequencing (NGS) workflow for clinical research of immuno-oncology therapies. Epic is looking to combine the MSI and CIN capabilities at a time when researchers have reported…